A new peptide-siRNA drug delivery system could revolutionise treatment for osteoarthritis by targeting pain and inflammation at the source.

Dr. Tejal Aslesh Tailor is an accomplished neuroscientist and molecular biologist with years of expertise in preclinical ...

Epigenetic changes do not alter the genetic code itself, but by changing how DNA is organized within the cell, epigenetic ...

MarkHerz Inc., a biotechnology company specializing in AAV-based gene therapies targeting cardiovascular and metabolic diseases, announced that it has signed a Memorandum of Understanding (MOU) on May ...

In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups ...

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

As newborn screening and rapid DNA sequencing become routine, we are poised to catch and treat inherited diseases at their ...

Neuroscientists can now make precise genetic tweaks to the neurons that are most affected by brain diseases such as Parkinson ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

This first-in-human trial is testing a highly unconventional method: delivering fat-derived stem cells from the patient ...